Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease in the INCREASE Trial

COMMENTED

Further Publications

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Nathan SD, Waxman A, Rajagopal S, Case A, Johri S, DuBrock H, De La Zerda DJ, Sahay S, King C, Melendres-Groves L, Smith P, Shen E, Edwards LD, Nelsen A, Tapson VF

doi: 10.1016/S2213-2600(21)00165-X

RECOMMENDED

Interstitial Lung Disease

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Alexander Turk, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

N Engl J Med

Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, Allen R, Feldman J, Argula R, Smith P, Rollins K, Deng C, Peterson L, Bell H, Tapson V, Nathan SD

doi: 10.1056/NEJMoa2008470

RECOMMENDED

Interstitial Lung Disease

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Schönfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, Günther A, RELIEF investigators.

doi: 10.1016/S2213-2600(20)30554-3

RECOMMENDED

Interstitial Lung DiseasePulmonary Fibrosis

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med.

Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, INBUILD trial investigators.

doi: 10.1016/S2213-2600(20)30036-9.

RECOMMENDED

Pulmonary Hypertension

Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial

Lancet Respir Med.

Sadushi-Kolici R, Jansa P, Kopec G, Torbicki A, Skoro-Sajer N, Campean IA, Halank M, Simkova I, Karlocai K, Steringer-Mascherbauer R, Samarzija M, Salobir B, Klepetko W, Lindner J, Lang IM

doi: 10.1016/S2213-2600

COMMENTED

Pulmonary Hypertension

Pulmonary hypertension in chronic lung disease and hypoxia

Eur Respir J.

Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, Weissmann N, Seeger W

doi: 10.1183/13993003.

RECOMMENDED

Interstitial Lung Disease

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med.

Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V

doi: 10.1016/S2213-2600(19)30341-8.

RECOMMENDED

AsthmaCOPD

Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial

Respir Res.

Gregoriano C, Dieterle T, Breitenstein AL, Dürr S, Baum A, Maier S, Arnet I, Hersberger KE, Leuppi JD

doi: 10.1186/s12931-018-0936-3.

COPDPulmonary Fibrosis

Pulmonary hypertension in advanced lung diseases: Echocardiography as an important part of patient evaluation for lung transplantation.

Clin Respir J.

Nowak J, Hudzik B, Jastrzebski D, Niedziela JT, Rozentryt P, Wojarski J, Ochman M, Karolak W, Żegleń S, Gierlotka M, Gąsior M

doi: 10.1111/crj.12608

Related content

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial

Pulmonary hypertension in chronic lung disease and hypoxia

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial

Pulmonary hypertension in advanced lung diseases: Echocardiography as an important part of patient evaluation for lung transplantation.